A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human
CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To assess
pharmacokinetic properties of rCD4 in humans. To obtain a preliminary indication of the
antiviral effects of rCD4 in patients with AIDS and AIDS related complex (ARC).